Dr Charles DeBattista, professor of psychiatry and behavioral sciences at Stanford University, discusses the evolving landscape of MDD treatment while on-site at Psych Congress 2023.
Dr Charles DeBattista, professor of psychiatry and behavioral sciences at Stanford University, discusses the evolving landscape of MDD treatment while on-site at Psych Congress 2023.
Greg Mattingly, MD, gives exclusive updates from day 2 of the National Academy of Sciences Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development Workshop.
Greg Mattingly, MD, gives exclusive updates from day 2 of the National Academy of Sciences Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development Workshop.
NAATP Director of Research and Education Annie Peters, PhD, LP, a presenter at the West Coast Symposium on Addictive Disorders, discusses best practices for implementing measurement-based care.
NAATP Director of Research and Education Annie Peters, PhD, LP, a presenter at the West Coast Symposium on Addictive Disorders, discusses best practices for implementing measurement-based care.
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
